17,261 trials
Diabetes Mellitus Type 2
Primary: Total and First Phase of Insulin Secretion (Insulinogenic Index and Stumvoll Index) After 90 Days — 0.41; 0.23; 1135.7; 309.0 index
Post-operative Cognitive Decline · Post-operative Delirium
Primary: Change From Baseline Cognitive Function
Metabolic Syndrome X
Primary: Triglyceride Levels at Week 12 — 148.0; 199.9 mg/dL — p=0.021
Lipodystrophy
Primary: Change in Log 10 Fasting Triglycerides. — 0.1; -0.2 log 10 mg/dl
Actinic Keratosis
Primary: Number of Responders — 19 Participants
Sleep Apnea · Sleep Disordered Breathing
Primary: Change in Apnea Hypopnea Index (AHI) From Baseline — 38.2; 34 apnea / hypopnea events per hour sleep
Psoriasis Vulgaris
Primary: The Adrenal Response to the ACTH Challenge Test Defined as the Serum Cortisol Concentration Obtained After 30 and 60 Minutes — 29; 1 Participants
Osteoarthritis, Hip · Osteoarthritis, Knee · Arthritis
Primary: Change From Baseline at Week 8 With Respect to the Weekly Mean of the Daily 24-hour Pain Intensity for the Index Joint as Measured by the Numeric Rating Scale (NRS)…
Alzheimer's Disease
Primary: Change in Regional Glucose Metabolism Between Week 24 and Baseline as Measured by 18F-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography (FDG-PET). — -0.032…
Malignant Gliomas · CNS · Brain Cancer
Primary: Determine the Efficacy of Perifosine in Patients With Recurrent/Progressive GBMs Not Taking EIAEDs as Measured by 6 Month Progression Free Survival/PFS. — 1.58; 2.12…
Multiple Myeloma
Primary: The Effectiveness of MV-NIS Therapy as Measured by the International Myeloma Working Group (IMWG) Guidelines
Nervous System Disease
Primary: Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) - Bladder — 575.1; 650.8 SUV x min
Acne Vulgaris
Primary: Change in HPA Axis Response as Measured by CST — 12.50; 22.95 mcg/dL
Lung Cancer
Primary: Objective Response Rate (ORR), Presented in Numbers of Participants — 0; 0; 1; 1 Participants
Ovarian Cancer · Fallopian Tube Neoplasms · Peritoneal Neoplasm
Primary: Part 2: Progression-Free Survival (PFS) — 18.9; 15.2 months